Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers.
Definitely NOT for traders or...
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired by Gilead Sciences (GILD)
Dicerna (DRNA) $3.30 to $38.25 up...
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10 Price Targets....
Dicerna (DRNA) up 78% Today. Being Acquired by Novo Nordisk (NVO) for $38.00.
We shoot and we score. Up 1,133% since adding to Watch List @ $3.00.
Our second $3.00 Watch List company getting acquired for over $1...
And We Have Our First MEME Stock! $2.00 to $29.95.
Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg)
Guess we were bound to stumble across a meemster sooner or later! This...
ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites
Gentleman, Start Your Engines?
ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study
Completion of the Study Expected by the...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021 @$1.80Cash has Risen From $3.3 Million...
Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).
Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal.
We've had a Long History With Dyadic Dating...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Citius announced that the DMC interim safety and...
Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial halt for Mino-Lok® (a rare but potential...
Latest article
Latest Research Report: $20 Price Target from Greenridge Global.
Here are four research reports below to peruse, all with price targets $20.00 or more...
While we don't issue price targets, it's comforting to see...
Three More Companies Suspended by SEC!
Millions of Investor's Dollars are Being Trapped.
These three companies had a combined market cap of $563 million at the time they were halted, whose...
AI Data Center Short – Jim Chanos
“If the economic life on these things is three years ... the whole economics of a lot of these deals kind of falls...
